Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > BUSINESS
BUSINESS
- Kaketsuken Submits 1st Japan-Made Hemophilia Inhibitor Treatment for Approval
October 9, 2013
- Takeda’s Norovirus Vaccine Misses Primary Endpoint in PI/II, but Reduces Vomiting, Diarrhea
October 9, 2013
- Chugai Files NDA for ALK Inhibitor Alectinib in Japan for NSCLC
October 9, 2013
- Onychomycosis Treatment Efinaconazole Licensed from Kaken Approved in Canada
October 9, 2013
- Astellas, US Biotech Venture to Collaborate on Mitochondrial Disease Therapies
October 8, 2013
- Quintiles Aims to Expand Business in Japan with More Employees: CEO
October 8, 2013
- Ethical Drug Sales Up 0.7% in August: Crecon Report
October 8, 2013
- 3 Combination Drugs for Asthma, COPD Get Approval to Fuel Competition; NHI Price Listing Expected in November
October 7, 2013
- Novartis AG Pharma Division Head Supports Ministry Panel’s Diovan Investigation Interim Report, Refuses to Comment on Whether Ads Were Exaggerated
October 7, 2013
- Nippon Shinyaku, Pfizer Japan Sign Deal for Promotional Activities for Tramal
October 7, 2013
- Novartis Japan Execs Face 30% Pay Cut amid Diovan Scandal, Compliance Advisory Board to Be Set Up
October 4, 2013
- Mundipharma Initiates Clinical Study of PTCL Treatment Pralatrexate in Japan
October 4, 2013
- Takeda, Tri-I TDI Conclude Research Deal
October 4, 2013
- Number of MRs Down Slightly to 63,846 as of March 2013; Are We Entering an Age of Decline for MRs?
October 4, 2013
- Nichi-Iko, South Korean Biotech Firm Partner Up on Biosimilar Business
October 3, 2013
- Nihon Chouzai to Increase Its Generic Portfolio to 1,000 in 2 Years: President Mitsuhara
October 3, 2013
- Asahi Kasei Pharma, Vernalis Sign Joint Research Agreement for New Drug Discoveries for Autoimmune Diseases
October 3, 2013
- Kissei, JCR to Jointly Develop Nesp Biosimilar
October 2, 2013
- Another Administrative Action Taken Against MTPC on Medway Injection; 3rd in 4 Years
October 2, 2013
- US FDA Approves Brintellix for Treatment of MDD in Adults: Takeda, Lundbeck
October 2, 2013
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…